NCT06888362 2026-01-28
Trial to Investigate GZ21T in Healthy Volunteers
Genzada Pharmaceuticals USA, Inc.
Phase 1 Completed
Clinical Trials
7 trialsNCT01449513 2025-03-07
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
LEO Pharma
Phase 1 Completed
NCT03643744 2024-12-19
Photodynamic Therapy-Induced Immune Modulation: Part III
Wright State University
Phase 1 Terminated
NCT05060237 2024-10-17
Study to Evaluate Safety and Tolerability of BF-200 ALA (AmeluzĀ®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT03322293 2022-03-09
Daylight Photodynamic Therapy for Actinic Keratosis
University of California, San Francisco
Phase 1 Completed
NCT04319159 2021-11-11
Study to Evaluate the Safety of BF-200 ALA (AmeluzĀ®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT00828568 2014-01-28
Bioequivalence Study of Two Imiquimod Cream 5%
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed